+44 330 818 7254Benny Budiman
Antiretroviral drug-related liver injury (ARLI) is a drug induced hepatotoxicity due to antiretroviral drugs (ARV). Antiretroviral drug-related liver injury (ARLI) is a common cause of morbidity, mortality and treatment discontinuation in HIV-infected patients. Several studies have described predisposing factors for ARLI, including body mass index (BMI) and cluster of differentiation 4 (CD4). The association between BMI and CD4 with ARLI remains unclear as some studies demonstrated different outcomes. This study is conducted to assess the association between low baseline BMI and CD4 cell count as risk factors for ARLI.
This is a clinical epidemiology study with cross-sectional design. Subjects are 75 HIV-AIDS patients on ARV therapy, in form of fixed dose combination drug (tenofovir, lamivudine, efavirenz), in HIV clinic (Teratai) Hasan Sadikin Hospital Bandung. Alanine aminotransferase (ALT) examination was done before starting ARV and repeated in the sixth month of therapy.
Share this article